January 20, 2017
Xintela looking for partners to reach patients faster, two main projects bring optimism
Xintela AB has reported positive results in its two main projects in regenerative medicine and cancer.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
January 20, 2017
Where do you stand against influenza
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
January 20, 2017
Sanofi’s M&A misses frustrate some investors in drugmaker
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
January 20, 2017
Bristol-Myers not asking for faster Opdivo/Yervov approval for first-line lung cancer in U.S.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
January 20, 2017
Avacta expects to license Affimer technology in 2017
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
January 20, 2017
Abzena nets $300 million for its ThioBridge technology
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
January 20, 2017
Seasonal Affective Disorder
Seasonal Affective Disorder (SAD) is a type of depression that comes and goes with the seasons, typically starting in the late fall and early winter and going away during the spring and summer. Depressive episodes linked to the summer can occur, but are much less common than winter episodes of SAD.
January 20, 2017
Cerenis satisfied with Q4 2016, expects good news from clinic in Q1 2017
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
January 20, 2017
Japanese MHLW OK’s Bayer’s cancer drug
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
January 20, 2017
Latvian Olainfarm sales up by 39% year to year, target topped by 6%
According to preliminary consolidated results of Latvian JSC Olainfarm for December 2016, sales of the Groups have reached €10.28 million, which represents an increase by 39% compared to December 2015.